Role of the NOD1/NF-κB pathway on bovine neutrophil responses to crude lipopolysaccharide

Wei, Liang-Jun; Tan, Xiaohong; Fan, Guo-Juan; Jiang, Yi; Shah, Qurban A.

doi:10.1016/j.tvjl.2016.02.006

Cited by 5 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with an elevated pretreatment neutrophil to lymphocyte ratio (NLR) exhibited worse disease-specific survival than patients without an elevated NLR . Clinical data correlate high neutrophil levels with a worse prognosis. , Reduced NOD1 expression has been observed in dysfunctional neutrophils, and treatments that blocked the NOD1/NF-κB pathway inhibited neutrophil migration and their phagocytic killing capacity . Stimulation with synthetic NOD1 ligands induced neutrophil recruitment in vivo. , Neutrophil counts in the C12-iE-DAP- or MDP-treated groups were much higher than the naive group and similar to those of the vehicle control group.…”

Section: Discussionmentioning

confidence: 84%

Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis

Wen¹,

Zheng²,

et al. 2018

J. Med. Chem.

View full text Add to dashboard Cite

Salutaxel (3) is a conjugate of docetaxel (7) and a muramyl dipeptide (MDP) analogue. Docetaxel (7) has been recognized as a highly active chemotherapeutic agent against various cancers. MDP and its analogues are powerful potentiators of the antitumor actions of various tumor-necrotizing agents. This article documents the discovery of compound 3 and presents pharmacological proof of its biological function in tumor-bearing mice. Drug candidate 3 was superior to compound 7 in its ability to prevent tumor growth and metastasis. Compound 3 suppressed myeloid-derived suppressor cell (MDSC) accumulation in the spleens of tumor-bearing mice and decreased various serum inflammatory cytokines levels. Furthermore, compound 3 antagonized the nucleotide-binding oligomerization domain-like receptor 1 (NOD1) signaling pathway both in vitro and in vivo.

show abstract

Section: Discussionmentioning

confidence: 84%

Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis

Wen¹,

Zheng²,

et al. 2018

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…coli mastitis [ 30 ]. Impairment of the NOD1/NF-κB pathway tends to downregulate mRNA levels of chemokine IL-8 [ 31 ]. As we further narrowed the scope of the important DEGs by finding the most important genes (CTSC, IL10, IL8, and IL18) (Fig.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic in silico analysis of bovine Escherichia coli mastitis highlights its immune-related expressed genes as an effective biomarker

Farmanullah

Liang

Khan

et al. 2021

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Background Mastitis is one of the major diseases causing economic loss to the dairy industry by reducing the quantity and quality of milk. Thus, the objective of this scientific study was to find new biomarkers based on genes for the early prediction before its severity. Methods In the present study, advanced bioinformatics including hierarchical clustering, enrichment analysis, active site prediction, epigenetic analysis, functional domain identification, and protein docking were used to analyze the important genes that could be utilized as biomarkers and therapeutic targets for mastitis. Results Four differentially expressed genes (DEGs) were identified in different regions of the mammary gland (teat cistern, gland cistern, lobuloalveolar, and Furstenberg’s rosette) that resulted in 453, 597, 577, and 636 DEG, respectively. Also, 101 overlapped genes were found by comparing 27 different expressed genes. These genes were associated with eight immune response pathways including NOD-like receptor signaling pathway (IL8, IL18, IL1B, PYDC1) and chemokine signaling pathway (PTK2, IL8, NCF1, CCR1, HCK). Meanwhile, 241 protein-protein interaction networks were developed among overlapped genes. Fifty-seven regulatory events were found between miRNAs, expressed genes, and the transcription factors (TFs) through micro-RNA and transcription factors (miRNA-DEG-TF) regulatory network. The 3D structure docking model of the expressed genes proteins identified their active sites and the binding ligands that could help in choosing the appropriate feed or treatment for affected animals. Conclusions The novelty of the distinguished DEG and their pathways in this study is that they can precisely improve the detection biomarkers and treatments techniques of cows’ Escherichia coli mastitis disease due to their high affinity with the target site of the mammary gland before appearing the symptoms. Graphical abstract

show abstract

“…This effect could be advantageous, since several studies have shown a correlation between elevated blood neutrophil count and poor clinical outcome in many cancers . Moreover, it has been shown that dysfunctional neutrophils express reduced levels of NOD1 and that treatments that blocked the NOD1/NF‐κB pathway resulted in inhibition of neutrophil migration and their phagocytic killing capacity . Due to these findings, it has been proposed that compound 40 inhibits neutrophil recruitment by blocking the NOD1 pathway.…”

Section: Nod Ligands As Anticancer Agentsmentioning

confidence: 99%

Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy

Nabergoj

Mlinarič-Raščan

Jakopin

2018

Medicinal Research Reviews

View full text Add to dashboard Cite

In the last decade, cancer immunotherapy has emerged as an effective alternative to traditional therapies such as chemotherapy and radiation. In contrast to the latter, cancer immunotherapy has the potential to distinguish between cancer and healthy cells, and thus to avoid severe and intolerable side‐effects, since the cancer cells are effectively eliminated by stimulated immune cells. The cytosolic nucleotide‐binding oligomerization domains 1 and 2 receptors (NOD1 and NOD2) are important components of the innate immune system and constitute interesting targets in terms of strengthening the immune response against cancer cells. Many NOD ligands have been synthesized, in particular NOD2 agonists that exhibit favorable immunostimulatory and anticancer activity. Among them, mifamurtide has already been approved in Europe by the European Medicine Agency for treating patients with osteosarcoma in combination with chemotherapy after complete surgical removal of the primary tumor. This review is focused on NOD receptors as promising targets in cancer immunotherapy as well as summarizing current knowledge of the various NOD ligands exhibiting antitumor and even antimetastatic activity in vitro and in vivo.

show abstract

Role of the NOD1/NF-κB pathway on bovine neutrophil responses to crude lipopolysaccharide

Cited by 5 publications

References 51 publications

Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis

Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis

Transcriptomic in silico analysis of bovine Escherichia coli mastitis highlights its immune-related expressed genes as an effective biomarker

Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy

Contact Info

Product

Resources

About